Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2023-03-29 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-03-29 English
FORM 4
Director's Dealing
2023-03-28 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Cidara Therapeutics, Inc. It registers additional shares under the company's 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan. Form S-8 is a registration statement used for securities issued under employee benefit plans. The document includes legal exhibits, signatures, and power of attorney but does not contain financial statements or earnings data. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing related to securities registration for employee plans, which fits best under the category of Regulatory Filings (RNS). The document length is 8967 characters, and it is a full filing, not a brief announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-23 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 23, 2023, reporting the financial results for the fourth quarter and year ended December 31, 2022. It specifically states that the financial results are provided via a press release attached as Exhibit 99.1. The text indicates that this is a current report announcing the earnings release rather than the full detailed financial report itself. The document length is 3732 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2023-03-23 English
CIDARA THERAPEUTICS, INC. 2022 FORM 10-K
Annual Report FY 2022
2023-03-23 English
FORM 4
Director's Dealing
2023-03-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.